NephroDI Therapeutics, a Biolocity portfolio company, has made waves in the medical field with its recent agreement to develop a first-in-class treatment for a rare genetic disease affecting the kidneys. This development brings new hope to patients and their families who have been waiting for a targeted therapy to address congenital Nephrogenic Diabetes Insipidus (NDI). This collaboration is a testament to the power of scientific innovation and industry partnerships in driving advancements in healthcare and improving patient outcomes.

Learn more about this exciting news here.

SIRPant Immunotherapeutics, Inc., a Biolocity portfolio company, has achieved a significant milestone in the field of immunotherapy. The company recently announced the FDA clearance of its Investigational New Drug (IND) application for SIRPant-M™, an autologous SIRPα^low activated macrophage immunotherapy. This exciting development marks a major step forward in the advancement of personalized and targeted treatments.

To learn more, visit the official announcement on SIRPant Immunotherapeutics’ website: https://sirpantimmunotx.com/news/sirpant-immunotherapeutics-announces-fda-clearance-of-ind-application-for-sirpant-m-autologous-sirp%ce%b1low-activated-macrophage-immunotherapy/.